Reduced cardiovascular risk after bariatric surgery is linked to plasma ceramides, apolipoprotein-B100, and ApoB100/A1 ratio Helen M. Heneghan, M.D., Hazel Huang, M.S., Sangeeta R. Kashyap, M.D., Heather L. Gornik, M.D., Arthur J. McCullough, M.D., Philip R. Schauer, M.D., Stacy A. Brethauer, M.D., John P. Kirwan, Ph.D., Takhar Kasumov, Ph.D. Surgery for Obesity and Related Diseases Volume 9, Issue 1, Pages 100-107 (January 2013) DOI: 10.1016/j.soard.2011.11.018 Copyright © 2013 American Society for Metabolic and Bariatric Surgery Terms and Conditions
Fig. 1 Framingham risk score at baseline (preoperatively) and 3 and 6 months after RYGB. Surgery for Obesity and Related Diseases 2013 9, 100-107DOI: (10.1016/j.soard.2011.11.018) Copyright © 2013 American Society for Metabolic and Bariatric Surgery Terms and Conditions
Fig. 2 Change in levels of apolipoprotein (Apo) B100 (A) and ApoB100/ApoA1 ratio (B) at 3 and 6 months after RYGB. Surgery for Obesity and Related Diseases 2013 9, 100-107DOI: (10.1016/j.soard.2011.11.018) Copyright © 2013 American Society for Metabolic and Bariatric Surgery Terms and Conditions